Related references
Note: Only part of the references are listed.Global, regional and national burden of primary liver cancer by subtype
Harriet Rumgay et al.
EUROPEAN JOURNAL OF CANCER (2022)
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy
Adrianne L. Jenner et al.
ISCIENCE (2022)
Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
R. E. Abrams et al.
SCIENTIFIC REPORTS (2022)
Simulations of tumor growth and response to immunotherapy by coupling a spatial agentbased model with a whole-patient quantitative systems pharmacology model
Alvaro Ruiz-Martinez et al.
PLOS COMPUTATIONAL BIOLOGY (2022)
Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells
Konstantinos Melissaropoulos et al.
FRONTIERS IN IMMUNOLOGY (2022)
Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm
Vijayalakshmi Chelliah et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review
Matthias Pinter et al.
JAMA ONCOLOGY (2021)
Application of subject-specific adaptive mechanical loading for bone healing in a mouse tail vertebral defect
Angad Malhotra et al.
SCIENTIFIC REPORTS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent
Xin Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Hanwen Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
Xinfang Yu et al.
BIOMEDICINES (2021)
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib
May Tun Saung et al.
ONCOLOGIST (2021)
Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration
Jane P. F. Bai et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor-Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy
Chang Gong et al.
CANCERS (2021)
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
Shima Makaremi et al.
BIOMEDICINES (2021)
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
Won Jin Ho et al.
NATURE CANCER (2021)
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
Sandra J. Casak et al.
CLINICAL CANCER RESEARCH (2021)
Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development
Huilin Ma et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
Model-Informed Artificial Intelligence: Reinforcement Learning for Precision Dosing
Benjamin Ribba et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.
Aiwu Ruth He et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant checkpoint blockade for cancer immunotherapy
Suzanne L. Topalian et al.
SCIENCE (2020)
PHD1 controls muscle mTORC1 in a hydroxylation-independent manner by stabilizing leucyl tRNA synthetase
Gommaar D'Hulst et al.
NATURE COMMUNICATIONS (2020)
From cells to tissue: How cell scale heterogeneity impacts glioblastoma growth and treatment response
Jill A. Gallaher et al.
PLOS COMPUTATIONAL BIOLOGY (2020)
Comparative Respiratory Physiology in Cetaceans
Andreas Fahlman et al.
FRONTIERS IN PHYSIOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Computational Modeling of Fructose Metabolism and Development in NAFLD
Yunjie Liao et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
Huilin Ma et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Multi-scale modeling of macrophage-T cell interactions within the tumor microenvironment
Colin G. Cess et al.
PLOS COMPUTATIONAL BIOLOGY (2020)
QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications
Richard J. Sove et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
Asymmetric paralog evolution between the cryptic gene Bmp16 and its well-studied sister genes Bmp2 and Bmp4
Nathalie Feiner et al.
SCIENTIFIC REPORTS (2019)
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
Mohammad Jafarnejad et al.
AAPS JOURNAL (2019)
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma
Ahmed Omar Kaseb et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
Lichun Ma et al.
CANCER CELL (2019)
Model-based virtual patient analysis of human liver regeneration predicts critical perioperative factors controlling the dynamic mode of response to resection
Babita K. Verma et al.
BMC SYSTEMS BIOLOGY (2019)
Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the US Food and Drug Administration's Office of Clinical Pharmacology
Manuela Grimstein et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Improving the generation and selection of virtual populations in quantitative systems pharmacology models
Theodore R. Rieger et al.
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Modeling the Dynamics of Human Liver Failure Post Liver Resection
Babita K. Verma et al.
PROCESSES (2018)
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018): Late-Breaking Abstracts: Washington, DC, USA. 7-11 November 2018
[Anonymous]
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Systemic therapy for hepatocellular carcinoma: beyond sorafenib
Patrick Boland et al.
CHINESE CLINICAL ONCOLOGY (2018)
Simulating PDGF-Driven Glioma Growth and Invasion in an Anatomically Accurate Brain Domain
Susan Christine Massey et al.
BULLETIN OF MATHEMATICAL BIOLOGY (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Characterization of the Immune Microenvironment in Hepatocellular Carcinoma
Mark Yarchoan et al.
CLINICAL CANCER RESEARCH (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models
Yougan Cheng et al.
AAPS JOURNAL (2017)
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
K. Haratani et al.
ANNALS OF ONCOLOGY (2017)
Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
Todd S. Crocenzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD
William B. Ashworth et al.
PLOS COMPUTATIONAL BIOLOGY (2016)
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
Hiroyuki Inoue et al.
ONCOIMMUNOLOGY (2016)
Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models
R. J. Allen et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy
Suresh Gopi Kalathil et al.
JCI INSIGHT (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury
Lisl K. M. Shoda et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Mojo Hand, a TALEN design tool for genome editing applications
Kevin L. Neff et al.
BMC BIOINFORMATICS (2013)
A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy
Benjamin Ribba et al.
CLINICAL CANCER RESEARCH (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Integrating epidemiological data into a mechanistic model of type 2 diabetes: Validating the prevalence of virtual patients
David J. Klinke
ANNALS OF BIOMEDICAL ENGINEERING (2008)
Share Paper
